Zura Bio (NASDAQ:ZURA) Trading Up 17.2% – Here’s What Happened

Zura Bio Limited (NASDAQ:ZURA)’s share price shot up 17.2% on Friday . The company traded as high as $5.25 and last traded at $5.32. 985,066 shares were traded during trading, an increase of 34% from the average session volume of 737,134 shares. The stock had previously closed at $4.54.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ZURA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Chardan Capital boosted their price objective on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Finally, Oppenheimer decreased their target price on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday, March 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Price Performance

The firm has a market cap of $504.29 million, a price-to-earnings ratio of -4.86 and a beta of 0.03. The firm has a fifty day simple moving average of $4.48 and a two-hundred day simple moving average of $5.25.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Equities analysts anticipate that Zura Bio Limited will post -0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its holdings in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after buying an additional 9,966 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Zura Bio in the 1st quarter valued at $72,000. JPMorgan Chase & Co. increased its position in shares of Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares during the period. Jane Street Group LLC purchased a new position in Zura Bio in the 2nd quarter worth $113,000. Finally, Atika Capital Management LLC purchased a new position in Zura Bio in the 3rd quarter worth $1,195,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.